Venus Remedies Limited (VENUSREM.BO)
INR 325.25
(-0.15%)
INR 325.25
(-0.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 711.8 Million INR | -15.28% |
| 2022 | 605.1 Million INR | 0.29% |
| 2021 | 625.76 Million INR | 4.07% |
| 2020 | 545.57 Million INR | 31.35% |
| 2019 | 373.14 Million INR | 45.24% |
| 2018 | 296.59 Million INR | -11.95% |
| 2017 | 397.71 Million INR | -23.85% |
| 2016 | 529.9 Million INR | -32.28% |
| 2015 | 778.08 Million INR | -2.98% |
| 2014 | 894.78 Million INR | -40.28% |
| 2013 | 1.38 Billion INR | 14.26% |
| 2012 | 1.2 Billion INR | 16.8% |
| 2011 | 1 Billion INR | 11.08% |
| 2010 | 905.97 Million INR | 22.12% |
| 2009 | 741.89 Million INR | 16.53% |
| 2008 | 636.64 Million INR | 16.65% |
| 2007 | 545.78 Million INR | 47.82% |
| 2006 | 369.21 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 112.6 Million INR | -51.86% |
| 2024 Q2 | 155 Million INR | 37.66% |
| 2023 FY | - INR | -15.28% |
| 2023 Q1 | 126.6 Million INR | -54.32% |
| 2023 Q3 | 120.4 Million INR | -42.23% |
| 2023 Q4 | 194.7 Million INR | 61.71% |
| 2023 Q2 | 208.4 Million INR | 64.61% |
| 2022 Q1 | 159.5 Million INR | 112.36% |
| 2022 Q4 | 277.16 Million INR | 132.71% |
| 2022 FY | - INR | 0.29% |
| 2022 Q3 | 119.1 Million INR | -24.43% |
| 2022 Q2 | 157.6 Million INR | -1.19% |
| 2021 Q2 | 302 Million INR | 60.81% |
| 2021 Q4 | 75.1 Million INR | -44.98% |
| 2021 Q1 | 187.8 Million INR | 849.06% |
| 2021 FY | - INR | 4.07% |
| 2021 Q3 | 136.5 Million INR | -54.8% |
| 2020 Q3 | 199.09 Million INR | -13.15% |
| 2020 Q2 | 229.23 Million INR | 1.49% |
| 2020 Q4 | 19.78 Million INR | -90.06% |
| 2020 Q1 | 225.86 Million INR | 60.34% |
| 2020 FY | - INR | 31.35% |
| 2019 Q3 | 125.67 Million INR | -10.57% |
| 2019 Q2 | 140.52 Million INR | 32.49% |
| 2019 Q4 | 140.86 Million INR | 12.09% |
| 2019 Q1 | 106.06 Million INR | 4715.32% |
| 2019 FY | - INR | 45.24% |
| 2018 Q1 | 104.94 Million INR | 0.0% |
| 2018 FY | - INR | -11.95% |
| 2018 Q4 | -2.29 Million INR | -103.97% |
| 2018 Q3 | 57.94 Million INR | -69.94% |
| 2018 Q2 | 192.72 Million INR | 83.65% |
| 2017 FY | - INR | -23.85% |
| 2016 FY | - INR | -32.28% |
| 2016 Q4 | 176.68 Million INR | 0.0% |
| 2015 FY | - INR | -2.98% |
| 2014 FY | - INR | -40.28% |
| 2013 Q1 | 316.07 Million INR | 11.33% |
| 2013 Q3 | 358.76 Million INR | 0.0% |
| 2013 Q4 | 342.78 Million INR | -4.45% |
| 2013 FY | - INR | 14.26% |
| 2012 Q1 | 298.46 Million INR | 0.0% |
| 2012 FY | - INR | 16.8% |
| 2012 Q2 | 290.58 Million INR | -2.64% |
| 2012 Q3 | 302.47 Million INR | 4.09% |
| 2012 Q4 | 283.9 Million INR | -6.14% |
| 2011 FY | - INR | 11.08% |
| 2010 FY | - INR | 22.12% |
| 2009 FY | - INR | 16.53% |
| 2008 FY | - INR | 16.65% |
| 2007 FY | - INR | 47.82% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 94.335% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -4.287% |
| Sigachi Industries Limited | 883.39 Million INR | 19.425% |
| Bal Pharma Limited | 345.59 Million INR | -105.966% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 89.626% |
| Medico Remedies Limited | 150.37 Million INR | -373.341% |
| Lasa Supergenerics Limited | -65.08 Million INR | 1193.732% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 119.077% |
| Alpa Laboratories Limited | 86.12 Million INR | -726.455% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 54.482% |
| Shilpa Medicare Limited | 2.58 Billion INR | 72.496% |
| Aarti Drugs Limited | 3.24 Billion INR | 78.089% |
| Lupin Limited | 36.96 Billion INR | 98.075% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 98.848% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 98.734% |
| Windlas Biotech Limited | 781.72 Million INR | 8.944% |
| Suven Life Sciences Limited | -992.78 Million INR | 171.698% |
| Eris Lifesciences Limited | 6.98 Billion INR | 89.812% |
| Valiant Laboratories Limited | 12.73 Million INR | -5487.574% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 92.375% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 125.224% |
| Ipca Laboratories Limited | 13.29 Billion INR | 94.648% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 51.874% |
| Achyut Healthcare Limited | 524 Thousand INR | -135739.885% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.486% |
| Bajaj HealthCare Limited | 444.51 Million INR | -60.129% |
| RPG Life Sciences Limited | 1.28 Billion INR | 44.456% |
| Mankind Pharma Limited | 28.09 Billion INR | 97.466% |
| Laurus Labs Limited | 8 Billion INR | 91.109% |
| Piramal Pharma Limited | 13.05 Billion INR | 94.548% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -65.429% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 97.967% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 92.598% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 93.725% |
| Unichem Laboratories Limited | 742.35 Million INR | 4.116% |
| Sequent Scientific Limited | 549.8 Million INR | -29.465% |
| Novartis India Limited | 1.26 Billion INR | 43.922% |
| Wanbury Limited | 985.49 Million INR | 27.772% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 84.781% |
| Wockhardt Limited | 1.08 Billion INR | 34.093% |
| Themis Medicare Limited | 562.6 Million INR | -26.518% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -120.058% |
| Jubilant Pharmova Limited | 8 Billion INR | 91.109% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 89.628% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.194% |
| Divi's Laboratories Limited | 25.43 Billion INR | 97.201% |
| NATCO Pharma Limited | 18.79 Billion INR | 96.213% |
| Gufic Biosciences Limited | 1.48 Billion INR | 51.921% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 72.692% |
| Ind-Swift Limited | 1.06 Billion INR | 33.168% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 76.387% |
| FDC Limited | 4.4 Billion INR | 83.829% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 960.422% |
| Granules India Limited | 8.6 Billion INR | 91.727% |
| Medicamen Biotech Limited | 245.66 Million INR | -189.75% |
| Alkem Laboratories Limited | 24.19 Billion INR | 97.058% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 69.798% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -5349.403% |
| Brooks Laboratories Limited | 41.72 Million INR | -1605.811% |
| Megasoft Limited | 284.73 Million INR | -149.991% |
| ZIM Laboratories Limited | 462.09 Million INR | -54.037% |
| Strides Pharma Science Limited | 3.76 Billion INR | 81.093% |
| Neuland Laboratories Limited | 4.74 Billion INR | 85.009% |
| Morepen Laboratories Limited | 1.72 Billion INR | 58.759% |
| Hikal Limited | 2.69 Billion INR | 73.561% |
| Indoco Remedies Limited | 2.64 Billion INR | 73.11% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 81.793% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -147.648% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -306.869% |
| Hester Biosciences Limited | 539.47 Million INR | -31.945% |